ABSTRACT
Objective: Due to the complicated compounds and the synergistic effect of multi-compounds, the quality control and assessment of Chinese materia medica (CMM) encounters a great challenge about how to identify the key compounds, which are directly correlated with its efficacy and safety. On the guidance of study on quality marker (Q-Marker), identification of Q-Markers was performed from Hedan Tablet (HDT) by the aid of the “spider-web” mode and hepatotoxicity evaluation derived from our previous researches and literatures. Methods: By the established ultra performance liquid chromatography with photodiode array detector (UPLC-PDA) method, online UPLC-DPPH· and offline antioxidant assay, 21 candidate compounds of HDT were systematically investigated and comprehensively evaluated by the “spider-web” mode for them properties of Q-Marker based on “content-stability-activity”. In addition, the Q-Markers related with hepatotoxicity based on our previous researches and literatures were identified. Results: Salvianolic acid B (SaB), quercetin-3-O-glucuronide (Qug), isoquercitrin (IQ) and hyperoside (Hyp) were adopted as the preferable Q-Markers of HDT according to the shaded area (A) of tested compounds in “spider-web” mode. Psoralen (Ps), isopsoralen (IP), psoralenoside (PO) and isopsoralenoside (IPO) were also strongly recommended as Q-Markers closely related with safety by considering hepatotoxicity of the accumulated Ps and IP and conversion between glycoside (PO and IPO) and aglycone (Ps and IP). Conclusion: This study provided scientific evidence for quality control and assessment of HDT, and also provided a meaningful reference for application of Q-Markers in CMM.
ABSTRACT
Objective To investigate the effects of Hedan tablet on serum adipocytokines and inflammatory factors in rats with metabolic syndrome.Methods The 24-rat model of metabolic syndrome were randomly divided into three groups(n=8,each):normal group were given normal diet,model group were given high-lipid and high-salt diet and intervention group were given high lipid and high salt dict plus Hedan tablet 6.0 g · kg-1 · d-1 by intragastric administration for 3 weeks.Body weight,blood pressure,blood levels of glucose,lipid,leptin,visfatin,adiponectin and CRP were measured in all rats at the beginning and the end of the study.Results Compared with normal group,model group (model versus normal) showed significantly increased serum levels (P ＜ 0.05) of weight,total cholesterol(TC),triglyceride (TG),low-density lipoprotein cholesterol (LDL-C),glucose,leptin(5.5±0.1 vs.5.2±0.0 mmol/L),visfatin(17.5±0.5 vs.16.6±0.0 mmol/L and CRP(1 676.6 ± 74.8 vs.1 642.3 ± 52.2 mmol/L),and showed significantly decreased (P ＜ 0.05) serum level of adiponectin(74.6±2.4 vs.81.3±2.1 mmol/L).Compared with 20 weeks of age group,the 23 weeks of age group(23 weeks versus 20 weeks)showed significantly decreased levels of weight,TC,TG,LDL-C,serum leptin(5.4±0.1 mmol/L vs.5.9±0.2 mmol/L),visfatin(16.7±0.4 mmol/L vs.17.7±0.6 mmol/L)and CRP(1 498.8±51.0 mmol/L vs.1 682.1±76.6 mmol/L(all P＜0.05),and showed significantly increased serum adiponectin level(81.2±3.0 mmol/L vs.73.9±3.1 mmol/L)(P＜0.05).But there was no significant change in model group between 20 weeks and 23 weeks of age.Conclusions Hedan tablet reduces the body weight and ameliorates blood lipid level in rats with metabolic syndrome.These effects may be related to regulation of Hedan tablet on adipocytokines and inflammatory factors.
ABSTRACT
Objective To investigate the effect of Hedan tablet combined with fluvastatin on serum LDL and heart rate variability in patients with coronary atherosclerotic heart disease (CHD).Methods 110 patients with coronary heart disease who were treated from March 2015 to June 2016 in our hospital were selected and randomly divided into observation group and control group, with 55 cases in each group.The patients in the observation group were treated with Hedan tablet combined with fluvastatin, and the control group was treated with fluvastatin.The changes of heart rate variability, blood lipids and inflammatory factors were compared before and after treatment, and the clinical curative effect was observed.Results After treatment, the total effective rate of the observation group was 96.4%, significantly higher than the control group 85.5%, the difference was statistically significant (P<0.05).The SDNN of the observation group was (85.42 ±9.11) ms and the SDANN was (49.11 ±5.13) ms, was significantly higher than those in the control group (76.87 ±8.12) ms, (44.16 ±4.76) ms.In the observation group, TC was (4.14 ±0.45) mmol/L, TG was (1.26 ±0.16) mmol/L, LDL was (2.08 ±0.31) mmol/L, significantly lower than the control group (4.78 ±0.51) mmol/L, (1.42 ±0.18) mmol/L, (2.43 ± 0.27) mmol/L, and HDL levels was (1.51 ±0.18) mmol/L, significantly higher than those in the control group (1.35 ±0.15) mmol/L, the difference was statistically significant (P<0.05), and the levels of inflammatory factors in the observation group were significantly lower than those in the control group, the difference was statistically significant (P<0.05).Conclusion Hedan tablets combined with fluvastatin in treating coronary atherosclerotic heart disease can effectively reduce serum LDL levels, improve heart rate variability, significantly improve the treatment effect.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effects of Hedan Tablet () on serum lipid profile, proprotein convertase subtilisin/kexin type 9 (PSCK9) and high-density lipoprotein (HDL) subfractions in patients with hyperlipidemia.</p><p><b>METHODS</b>Thirty-seven patients with hyperlipidemia were randomized to treatment with Hedan Tablet 4.38 g/day as Hedan group (18 cases) or placebo (19 cases) as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups respectively.</p><p><b>RESULTS</b>Hedan treatment for 8 weeks mildly decreased serum low-density lipoprotein cholesterol (LDL-C) levels, while no changes were found in total cholesterol (TC), triglycerides (TG) and PCSK9 concentrations. Furthermore, Hedan treatment increased the concentration of large high-density lipoprotein cholesterol (HDL-C) and the percentage of large HDL subfraction, while decreased the concentration of small HDL-C and the percentage of small HDL subfraction without changing serum HDL-C levels in patients with hyperlipidemia.</p><p><b>CONCLUSION</b>Hedan treatment of 4.38 g per day for 8 weeks could confer a favorable effects on serum LDL-C concentration as well as HDL subfractions.</p>
Subject(s)
Female , Humans , Male , Middle Aged , Drugs, Chinese Herbal , Therapeutic Uses , Hyperlipidemias , Blood , Drug Therapy , Lipoproteins, HDL , Blood , Proprotein Convertase 9 , Metabolism , Subcellular Fractions , MetabolismABSTRACT
Objective To observe the effects of Hedan tablet on cytokines and oxidation factors in APOE-/-mouse, and to explore its effect on atherosclerosis and to explore its behind mechanism. Methods APOE-/-mice (n=50) were randomly divided into control group, model group, low dose Hedan tablet treatment group, high dose Hedan tablet treatment group and simvastatin treatment group. Mice in control group were given normal feed while mice in other groups were fed with high cho?lesterol diet. Hedan or Simvastatin was administrated intra-gastrically while normal saline was given to model group in the same route. After 12 weeks, mice were sacrificed to observe the mRNA level of tumor necrosis factor-α(TNF-αmRNA) in aorta by RT-PCR. Mean while, serum levels of interleukin-1 (IL-1), interleukin-10 (IL-10), malonaldehyde (MDA) and su?peroxide dismutase (SOD) were determined in different groups. Results Compared with control group, TNF-αmRNA tran?scription level as well as serum levels of IL-1 and MDA significantly increase while serum levels of IL-10 and SOD de?creased remarkably in model group, (P<0.01). Compared with model group, mRNA levels of TNF-αas well as serum levels of IL-1 and MDA were significantly decreased while serum levels of IL-10, SOD were greatly increased in low dose and high dose Hedan tablet treatment groups as well as in simvastatin treatment group (P<0.01). Conclusion Hedan tablet inhibit the formation of atherosclerosis through its anti-oxidation role and anti-inflammation role.